A subsequent tumour board conference recommended the continuation of treatment with the BRAF/MEK inhibitor and early follow-up care in accordance with the guidelines, taking into account the patient's age and a Grade 2 on the Eastern Cooperative Oncology Group Performance Status Scale. This evidence concerns the gene BRAF and neoplasm.